Ziņa ievietota: 01.03.2021
Uz mākslīgā intelekta tehnoloģijām balstīta diagnostikas risinājuma izstrāde, kas varētu prognozēt plaušu vēža imūnterapijas ilgtermiņa efektivitāti.
2021. gada 1. martā SIA “Aimuno” sadarbībā ar Latvijas Universitāti ir uzsākuši īstenot saimniecisku projektu, kurā starpdisciplināra patoloģijas, bioloģijas, bioinformātikas, datu zinātnes, unmākslīga intelekta zinātnieku komanda ir nokomplektēta ar mērķi veikt uz mākslīgā intelekta tehnoloģijām balstīta diagnostikas risinājuma izstrādi, kas varētu prognozēt plaušu vēža imūnterapijas ilgtermiņa efektivitāti.
Projektā ir izstrādātas sešas aktivitātes: (1) zinātniskās literatūras un patentu izpēte, (2) piekļuve datiem un datu kopas pabeigšana, (3) tehnoloģiju izstrāde, (4) tehnoloģiju novērtēšana darbības vidē, (5) tehnoloģiju optimizācija un ( 6) informācijas izplatīšana.
Projekta kopējās attiecināmās izmaksas ir EUR 675 182,83 un ERAF līdzfinansējums ir EUR 475 841,71 apmērā.
To paredzēts īstenot 12 mēnešu laikā līdz 2022. gada 28. februārim.
Pathology slides
DNA
Medical data
RNA
Combined biomarker
1 April 2021
Developing an AI-based diagnostic solution that could predict the long-term effectiveness of lung-cancer immunotherapy.
On 1 April 2021, Aimuno, in cooperation with The University of Latvia has launched a project in which a team of interdisciplinary pathology, biology, bioinformatics, data science, and artificial intelligence scientists have been completed with the aim of developing a diagnostic solution based on artificial intelligence technologies that could predict the long-term effectiveness of immunotherapy for lung cancer.
The project has developed six activities: (1) research of scientific literature and patents, (2) access to data and completion of the data set, (3) technology development, (4) technology assessment in the operational environment, (5) technology optimization and (6) information dissemination.
The total eligible costs of the project are EUR 675 182.83 and the ERDF co-financing is EUR 475 841.71
It is expected to be implemented within 18 months by 30 September 2022.
1 July 2021
1) Research of scientific literature and patents was finished 2) in connection with the access to data and completion of the data set the AImuno team started negotiations with one of the biggest Israeli biobanks to get access to the additional data for the project. AImuno started the process of building a collaboration with one of the biggest healthcare centres in North America. This collaboration will be beneficial both for data access and expertise in the area. 3) the pilot study about the elaboration of a novel immunotherapy prediction tool has been started. 95 patients with non-small cell lung cancer were retrospectively enrolled in the study. The clinical, histopathological data were analyzed. In addition, the peritumoral lymphocytes were analyzed. PD-L1- expression by immunohistochemistry and EGFR mutation by PCR was assessed. The comparative analysis between clinical, histopathological, immunohistochemical and genetic findings was performed. 4) the technology development activities proceed PoC using open-source data 5) relating to information dissemination, AImuno has held numerous internal calls with relevant experts in the area, demonstrating high interest in our research. We are currently looking for relevant scientific conferences to build further public connections for the company.
